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Background
More than 60% of the total HIV-1 infections worldwide
are dominated by clade B and C. To stop the epidemic,
effective prevention methods (e.g. microbicidal gel) are
of extreme importance. Carbohydrate binding agents
(CBAs) are very good microbicide candidates. We pre-
viously showed that various CBAs act synergistic with
tenofovir against HIV-1 [1].
Griffithsin (GRFT), isolated from the red alga Griffithsia
sp., shows very potent and broad-spectrum anti-HIV activ-
ity and recombinant forms can easily be produced [2,3].
Materials and methods
HIV-1 replication was measured in MT-4 cells and per-
ipheral blood mononuclear cells (PBMCs) by MTS
method and p24 Ag ELISA respectively. Synergism was
calculated using CalcuSyn software (Biosoft, Cambridge,
UK) based on the median effect principle [4]. Combina-
tion indices (CI) < 0.9 are synergistic, 0.9 < CI < 1.1 are
additive and CI > 1.1 are antagonistic.
Results
We evaluated combinations of GRFT against HIV-1
clade B and clade C isolates with various glycosylation
patterns on the viral envelope in PBMCs and MT-4
cells. In all combinations tested against clade B viruses
BaL (R5) and NL4.3 (X4), GRFT showed synergistic
activity with tenofovir, maraviroc, AMD3100 and enfu-
virtide, based on the median effect principle with combi-
nation indices (CI) varying between 0.34 and 0.64 at the
calculated EC95-level. Against the clade C viruses,
ZAM18, DJ259 and ETH2220 (all R5), Cl-values varied
between 0.70 and 0.79. The CI correlated with increased
antiviral activity of each individual compound.
Conclusions
The evaluated two drug combinations increase their
antiviral potency and support further clinical investiga-
tion and evaluation in preexposure prophylaxis in the
context of HIV-1 clade B and clade C infections. Differ-
ence in glycosylation motifs in gp120 have little, if any,
effects on the antiviral activity of GRFT.
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